Catch up on today’s top five analyst upgrades with this list compiled by The Fly: 1. Emergent BioSolutions (EBS) upgraded to Buy from Neutral at Goldman Sachs with analyst Dana Flanders saying he sees an “underappreciated opportunity” for Emergent to expand into other verticals, highlighted by Narcan nasal spray. 2. Michael Kors (KORS) upgraded to Buy from Neutral at UBS and to Overweight from Neutral at Piper Jaffray. 3. Parker-Hannifin (PH) upgraded to Outperform from Market Perform at Wells Fargo with analyst Andrew Casey sayoing the recent selloff has created an opportunity “to get back on board the PH stock train.” 4. Ingredion (INGR) upgraded to Neutral from Sell at Citi with analyst David Driscoll saying the worst is now likely behind the company’s North American operations, which should resume growth in 2019 “when many of the transitory 2018 issues will be in the rear view mirror.” 5. VeriSign (VRSN) upgraded to Neutral from Underweight at JPMorgan and to Outperform from Neutral at Baird. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage, (click here.):(http://thefly.com/streetResearch.php)
previous post
next post